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Gene transfer approaches using viruses such human adenovirus (HAdV) may provide an alternative treatment for diseases involving
hematopoietic cells.
Better understanding of the cellular mechanisms by which the HAdV introduces DNA into these cells should help in vector design. We
examined HAdV intracellular delivery in several cell lines including B and T lymphocytes. We demonstrated that HAdV resistance in most B
lymphocytes is the result of moderate HAdV uptake. In contrast, high levels of coxsackie and HAdV receptor (hCAR) are expressed on the
surface of HSB2 (T cells), allowing efficient binding and uptake but no transgene expression, probably because of deficient endosomolysis
and subsequent exocytose. This work demonstrates the existence of hCAR-dependent and -independent endocytic route in hematopoietic
cells. Moreover, it precises the intracellular barriers to be overcome by HAdV in such cells to be infectious and gives previous information’s
to design new vectors for gene transfer.
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Current cancer therapies of hematological malignancies
do not obtain a good patient survival rate, so novel
approaches to treat these diseases merit study. Gene therapy
represents an alternative form of treatment of cancer and
may be used to treat hematopoietic malignancies. Indeed,
the inability of patients to reject neoplastic cells seems to be
due in part to an immune deficiency that is often observed
with such diseases (Wierda and Kipps, 2000). Thus, it is of
interest to consider gene transfer of molecules that stimulate
the immune response in malignant cells to provoke cell
death.
At present, most methods of viral gene transfer do not
give efficient transduction of primary lymphocytes. Recom-
binant human adenoviruses (HAdV) are powerful vectors0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: colin@lille.inserm.fr (M. Colin).for gene therapy because they can be obtained at a high titer
(up to 1012 particles/ml) and can infect a wide variety of
dividing and nondividing cells (Danthinne and Imperiale,
2000). Moreover, the quiescent nature of leukemia cells
makes HAdV promising vectors for leukemia gene therapy.
Furthermore, these viruses are very efficient in cell and
nuclear entry leading to a high level of gene expression. In
spite of the new generation of recombinant HAdV vectors
(Armentano et al., 1997; Clemens et al., 1996; Danthinne
and Imperiale, 2000) and relatively high transduction levels
(Crystal, 1995), several problems limit their usefulness
especially with regard to the immune and inflammatory
responses they induce (Gahery-Segard et al., 1997). In
addition, HAdV receptors are found on the surface of many
cell types, which could result in dissemination of vector to
many organs, especially the liver (van der Eb et al., 1998),
and exclude the possibility of specific transfer of genetic
material.
The ability of HAdV to infect hematopoietic cells is
controversial, and it is still not clear if these viruses hold
promise for treatment of leukemia (Huang et al., 1997; Li et
al., 2001; Meeker et al., 1997; Wierda and Kipps, 2000).
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expressing CD154 could be used for gene therapy of
chronic lymphocytic leukemia (Wierda et al., 2000). These
results were confirmed in 2001 by Brenner et al. (Takahashi
et al., 2001).
To date, most studies of HAdV gene transfer are
performed on HAdV-permissive cells. Little is know about
HAdV gene transfer into hematopoietic cells and the
mechanisms responsible for infection. HAdV gene transfer
efficiency is directly correlated to the capacity of the cells
to correctly transport genetic material into the nucleus.
This efficacy is the result of multiple steps. The binding of
subgroup C HAdV to the cell surface is first initialized by
a primary high-affinity-interaction between the capsid fiber
knob of the virus (Roelvink et al., 1999) and a 42-kDa cell
surface glycoprotein receptor termed the coxsackie and
adenovirus receptor (CAR) (Bergelson et al., 1997; Tomko
et al., 1997). This is followed by an interaction of the
penton base RGD-motif of the virus with cellular co-
receptors, especially integrins avh3, avh5, aMh2, and
a5h1, leading to HAdV clathrin-coated pit endocytosis
(Bai et al., 1993; Bergelson et al., 1997; Chiu et al.,
1999; Davison et al., 1997; Huang et al., 1996; Svensson,
1985; Wickham et al., 1993; Wickham et al., 1994). More
recently, a third cell surface interaction with heparan
sulfate glycosaminoglycans has been identified for sub-
group C HAdV (Dechecchi et al., 2001). HAdV uptake
requires signaling events mediated by phosphatidylinositol-
3-OH kinase (PI3K) and the Rho family of small GTPases
(Li et al., 1998). The virus is then released from endo-
somes into the cytoplasm after membrane lysis, and the
genome is translocated to the nucleus by interaction with
the nuclear pore complex (NPC) machinery (Greber and
Kasamatsu, 1996; Trotman et al., 2001).
The inefficiency of HAdV vectors, particularly in he-
matopoietic cells, is often attributed to the paucity of the
primary HAdV receptor coxsackie and HAdV receptor
(hCAR) (Rebel et al., 2000). However, only a few studies
have analyzed precisely the causes of this non-permissivity
and have only analyzed early steps in the entry process
(Huang et al., 1996; Mentel et al., 1997; Nemerow and
Stewart, 1999). The function of aMh2 and aLh2 in virus
attachment to monocytic cells was suggested by Huang et
al. (1996); however, it seems that aV integrins are required
for virus entry into hematopoietic cells. The elucidation of
the mechanisms that underlie both the extracellular and the
intracellular aspects of HAdV trafficking will have a great
impact on the molecular biology of these viruses and on
the development of efficient adenoviral gene transfer
vectors.
These factors incited us to examine hematopoietic cell
resistance to HAdV infection by asking the following
question. Are alterations in tropism the only explanation,
or do intracellular steps inhibit HAdV gene transfer? To
answer this question, we compared the HAdV infection
efficiency in different hematopoietic cell lines including Band T cells and analyzed different steps from plasma
membrane binding to gene expression. This study allowed
us to determine the intracellular barriers to gene transfer in
hematopoietic cells with the aim of optimizing future
adenoviral constructions.
These results clearly demonstrate that the inefficiency of
HAdV could be the result of several defects, including
reduce binding, reduced intracellular uptake, and reduced
endosomolysis. These defects are cell specific, as previ-
ously described (Sieczkarski, 2002). We confirm validity
of the generally accepted gene transfer model, which
requires a variety of factors to be in place for successful
transgene expression. Alterations at any point in this
complex can decrease or block cellular transduction.
Moreover, we demonstrate the existence of hCAR-depen-
dent and -independent endocytic entry as previously de-
scribed for fibroblast cells (Hidaka et al., 1999). Authors
demonstrated that hCAR deficiency on fibroblast could be
circumvented either by supplying hCAR or by modifying
the HAdV fiber to bind other cell-surface receptors. Our
work gives us precious data to modified HAdV with
specific targeting of hematopoietic cells. The solution to
the inefficiency of HAdV in B cells could be the devel-
opment of strategies to redirect this virus using hCAR-
independent endocytic pathways. Moreover, the choice of
the targeted receptor is determinant because it must be cell
specific not only for binding but also for all subsequent
intracellular steps.Results
Four B lymphocytes cell lines were included in this
study: Daudi, Raji, C and D cells, the latter two were B
cells obtained from healthy donors and immortalized with
EBV. A pre-B cell line (Reh) and a more differentiated B
cell line (plasmocytes U266) were also studied. Finally,
two T cell lines, Jurkat and HSB2 cells and pre-erythro-
megacaryocytes K562, were studied. These cells were
studied in comparison to adenoviral permissive cells
HEK293, A549, and HeLa cells that have been studied
previously for adenoviral transduction (Glotzer et al.,
2001; Greber et al., 1993; Greber et al., 2001; Leopold
et al., 2000; Li et al., 1998; Mabit et al., 2002; Miyazawa
et al., 1999; Nakano et al., 2000; Trotman et al., 2001;
Vincent et al., 2001).
Infection efficiency of the adenovirus of different
hematopoietic cell lines
We first analyzed h-galactosidase reporter gene expres-
sion after infection of hematopoietic cells with HAdV. For
this, several cell lines that included T and B lymphocytes
were infected with a recombinant HAdV (multiplicity of
infection [MOI] of 30) vector containing h-galactosidase
reporter gene under the control of the immediate early
M. Colin et al. / Virologypromoter of CMV (Renaut et al., 2002). The concentra-
tion used in this study was determined after performing
cytotoxicity assays as previously described (data not
shown) (Vermes et al., 1995) and to obtain detectable
h-galactosidase activity in some B cell lines. The results
presented here (Fig. 1) show that most hematopoietic cell
lines except U266 plasmocytes were inefficiently trans-
duced with HAdV in comparison to HEK293, HeLa, and
A549 cells (permissive HAdV cells). Immortalized B
lymphocytes: C, and D cell lines were not well trans-
duced with HAdV and gave approximately the same
results as T cell lines (Jurkat and HSB2). These results
confirm previous studies showing that HAdV vectors are
not efficient in transducing hematopoietic cell lines.
However, it is of interest to note that h-galactosidase
gene expression in plasmocytes was 60% of the level in
permissive HEK293 cells. Moreover, Fig. 1B demonstrat-
ed that majority of plasmocytes U266 (87%) express h-
galactosidase. Thus, for efficient gene therapy of T or B
lymphocytes with HAdV, it is imperious to enhance the
transduction levels.Fig. 1. Adenovirus-mediated h-galactosidase gene expression in different cell lin
medium containing recombinant HAdV5hgal (MOI of 30). Twenty-four hours late
expressed as milliunits of h-galactosidase per milligram of cellular protein. (B) Ce
positive cells expressing h-galactosidase reporter gene was determined using stanHematopoietic cell lines express variable levels of hCAR on
their cell surface
The low transduction efficiency with HAdV is often
attributing to the paucity of hCAR. Thus, to understand
the differences observed in the h-galactosidase expression,
we analyzed the hCAR protein levels on these cell lines.
This was performed by immunofluorescence and flow
cytometry using an anti-hCAR primary antibody detected
with a secondary FITC antibody. Our result show that
except for the Reh, C, and HSB2, low levels of hCAR were
present on the plasma membrane of most of the hematopoi-
etic cell lines tested (Fig. 2). Plasma membrane localization
of hCAR was confirmed by confocal microscopy (data not
shown). It should be noted that HSB2 cells, a T lympho-
cytes cell line, show very high percentage of positive cells.
However, these cells are not permissive to HAdV as shown
in Fig. 1. The results suggest that the levels of hCAR are not
sufficient for efficient adenoviral transduction of HSB2,
Reh, and C cells. Likewise, hCAR is not expressed on
U266 plasmocytes, yet these cells seem to be permissive to
320 (2004) 23–39 25es. (A) Cells in suspension were incubated for 2 h at 37 jC in serum-free
r, cells were lysed for determination of the h-galactosidase activity, which is
lls were treated as described above except that after 24 h, the percentage of
dard assay with o-nitrophenyl-h-D-galactopyranoside as substrate.
Fig. 2. Expression of hCAR receptors on the surface of hematopoietic cells. Cells in suspension were firstly incubated with 20 Ag/ml of anti-hCAR antibody for
1 h at RT and secondly with 40 Ag/ml of a secondary FITC-conjugated antibody for 45 min at room temperature. Cytofluorometric analyses were performed
and results expressed as the percentage of positive cells for hCAR antibody (hatched bars) or isotype antibody (black bars).
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alternative pathways for adenoviral infection of hematopoi-
etic cell lines exist and that they may not involve hCAR
especially for plasmocytes.
Expression of CD18 and CD11a integrins but neither
CD51/61 nor CD11b on hematopoietic cell lines
Previous studies suggested that avh3 were not expressed
on hematopoietic cells in contrast to integrins containing the
h2 subunits (Huang et al., 1995; Huang et al., 1996). We
then analyzed the pattern of integrins expression including
CD18 (h2), CD11a (aL), and CD11b (aM) subunits on
different hematopoietic cell lines.
Our results confirm low expression of integrins avh3
(CD51/61) on most hematopoietic cell lines in comparison
to epithelial cell lines (data not shown), but h2 subunits
expression on Raji, C, D, and HSB2 cells. However, low
levels of these subunits were detected on Daudi and Jurkat
cell lines (Fig. 3). The absence of integrins avh3, a co-
receptor necessary for hCAR-dependent HAdV entry,
could explain why HSB2 cells are not permissive to
HAdV. However, it is still not clear why some B cell
lineages, particularly plasmocytes U266, seem to be per-
missive to HAdV. To answer this question, we determined
the aM and aL levels on these cells. The aL subunit is
expressed on HSB2, Jurkat, and Raji cells, and also on the
two immortalized B lymphocytes cell lines C and D with,
respectively, 98%, 13%, 54%, 35%, and 75% of positive
cells. We were not able to detect any aM expression on
most cell lines tested, only Raji and B lymphocytes
obtained from patients express very low levels (<10% of
positive cells) of these integrins (data not shown). In
conclusion, our results show that two known co-receptors
for HAdV uptake, avh3, and aM are not present on
hematopoietic cells. These results suggested those alterna-tive HAdV entry pathways independent of avh3, and aM
exist especially for plasmocytes.
Binding of adenovirus to different hematopoietic cell lines
To study the binding ability of the HAdV to hematopoi-
etic cell lines, we radiolabeled the viral capsid proteins with
[35S]-methionine and cysteine as described in the Materials
and methods. After attachment, cells were scrapped, lysed,
and the radioactivity was quantified and normalized to the
protein concentration. The highest level of binding was
observed with HEK293 cells, which are permissive to the
HAdV (Fig. 4A). When compared and normalized to
HEK293 cells, we observed that Jurkat and HSB2 (T cells)
gave, respectively, 32.8 (+/0.05)% and 76.26 (+/0.3)%
of binding. When competition studies using anti-hCAR
antibody were performed, binding of HAdV5 on HSB2
cells is completely abolish. These data demonstrate that
HAdV5 is able to attach to HSB2 cells using hCAR
receptor. Yet, these cells showed a low level of h-galacto-
sidase activity (Fig. 1) suggesting that intracellular events
blocked transgene expression. The HAdV binding ability of
B cells is variable and reached 51.9% for C cells. These
cells lack hCAR (Fig. 2) but express CD18 and CD11a (Fig.
3). It is of interest to note that the pattern of binding
corroborated with aLh2 expression of hematopoietic cell
lines.
Uptake of adenovirus in hematopoietic cells
To determine further the extra and intracellular barriers to
gene transfer in the hematopoietic cell lines tested, we
analyzed HAdV uptake. This was first performed using
radiolabeled HAdV as described above for binding, excep-
ted that after binding, the cells were incubated at 37 jC for
the desired time to allow for entry. The results presented in
Fig. 3. Cytofluorometric analysis of CD18 (h2) and CD11a (aL) on hematopoietic cells. Integrin expression was determined after incubation of the cell
suspension for 60 min at RT with 25 Ag/ml of FITC-labeled antibodies against CD18 (left panel) or CD11a (right panel). FACS analyses were performed after
cells fixation with 1% PFA. Controls consist of cells incubated under the same conditions with an isotype antibody.
M. Colin et al. / Virology 320 (2004) 23–39 27Fig. 4B show that after a 2-h incubation period at 37 jC,
U266 and HSB2 cells present higher uptake levels than
HEK293 cells. Thus, this correlates well with the h-galac-
tosidase expression observed for U266 but not for HSB2cells. Thus, the low level of reporter gene expression of
HSB2 cells is not due to a lack of uptake of HAdV.
To directly quantify viral DNA, we developed a real-time
PCR assay. To this aim, total DNAwas extracted from cells
Fig. 4. Binding and uptake of [35S]-labeled HAdV5hgal adenovirus to hematopoietic cells. (A) Cells in suspension were incubated for 60 min at 4 jC with 106
cpm of radiolabeled HAdV5hgal per 106 cells in serum-free medium. After rinsing with PBS, cells were lysed in 0.1% NaOH, the radioactivity was
determined, and the results were normalized to the cellular protein concentration. (B) After binding at 4 jC, a further chase period of 15 (open bars), 30 (closed
bars), or 120 (hatched bars) min at 37 jC was performed. Cells were treated as described above. (C) Cells in suspension were incubated without (blank bars),
with 103 (black bars), or with 104 (hatched bars) PP/cells of HAdV5hgal 2 h at 37 jC in serum-free medium. After collecting, cells were rinsed once with
trypsin 0.25% to eliminated cell-surface particles. DNA extraction and PCR amplification were performed as described in Materials and methods. Results are
expressed as nanograms of viral DNA normalized to nanograms of albumin DNA.
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described in Materials and methods and normalized to
cellular albumin gene. The results presented in Fig. 4C
confirmed those obtained with radiolabeled HAdV pre-
sented in Fig. 4B and suggest a low uptake ability in some
B cells lines (Reh, Raji, C, and D) but not in T cell lines
(Jurkat and HSB2).To further confirm these results, we examined the
intracellular transport of HAdV using 5-6-carboxyfluores-
cein-succinimidyl ester (FAM) fluorescently labeled HAdV
particles. Fluorography and Coomassie blue staining of SDS-
PAGE-fractionated virus particles were performed to verify
labeling of HAdV. Basic proteins associated with the viral
DNA as well as capsid proteins were labeled allowing us to
M. Colin et al. / Virology 320 (2004) 23–39 29follow intracytoplasmic and intranuclear adenoviral localiza-
tion (data not shown).
Different cell lines were then incubated in the presence of
FAM-HAdV for 60 min at 4 jC, and then a chase period of
30 min at 37 jC was performed. Cells were then treated or
not with trypsin 0.25% to remove cell surface-bound HAdV
particles. The uptake was quantified using FACS analysis.
The results presented in Fig. 5A confirmed that HAdV
uptake was limiting for some B cells especially for Reh,
C, and D cells.
After quantifying precisely fixation and uptake levels
using radiolabeled HAdV5, we have estimated uptake
efficiency in each cell lines. Bound HAdV particles (30–Fig. 5. Uptake of FAM-labeled HAdV2. (A) Cells in suspension were incubated
medium. After washing, a chase period of 30 min was performed at 37 jC. Cells
trypsin 0.25% to remove cell-bound particles. Quantification of labeled particles w
were treated under the same conditions, except that a chase period of 60 min at 37
microscope slide, cells were fixed and nuclei were stained with propidium iodide
fluorophores (FAM, green and propidium iodide, red) are shown. The scale bar r35%) entered into Raji or Daudi cells, and this level reached
60% for HSB2 and U266 cells (Data not shown). These
results confirmed that uptake does not represent a barrier to
T cell gene transfer. After a chase period of 60 min at 37 jC,
internalization in T cells (HSB2 and Jurkat) is lower than in
permissive cells, suggesting possible degradation and then
exocytose of HAdV particles in these cells (Fig 5B).
The adenovirus uses different types of endocytic routes to
penetrate into hematopoietic cells
HAdV are known to enter cells by a clathrin-coated pit
endocytosis pathway (Chiu et al., 1999). In order to examinefor 60 min at 4 jC with 1011 PP/ml of FAM-labeled HAdV in serum-free
were then treated in the presence (closed bars) or absence (hatched bars) of
as performed, after cells fixation with 1% PFA, by flow cytometry. (B) Cells
jC was observed and cells were not treated with trypsin. After plating on a
and confocal microscopy performed. Merged confocal images of the two
epresents 10 AM.
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internalized human transferrin. This molecule is known to
enter into cells via a clathrin-coated pit endocytosis pathway
(Huebers and Finch, 1987; Le Borgne and Hoflack, 1998).
Our results reveal a relative correlation between h-galacto-
sidase gene expression and transferrin uptake (Fig. 6A).
This could suggest that clathrin-coated pit endocytosis is
required to obtain efficient HAdV infection. Apparently, the
endocytic entry route used by HAdV vectors in HSB2 cells
does not allow for efficient gene transfer. We then postulated
that HAdV could internalize cells independently of clathrin-
coated pits. This concept was recently demonstrated for
influenza virus endocytosis (Sieczkarski and Whittaker,
2002) and for interleukin 2 receptors (Lamaze et al.,
2001). Thus, we performed co-localization studies using
confocal microscopy. We observed that in A549 cells, the
HAdV co-localizes with TRITC-labeled transferrin but not
with 1 AM Nile red-labeled fluorospheres (Fig. 6B). Nile
red-labeled fluorospheres were used as a marker of phago-
cytosis. In contrast, HSB2 internalized a low level of
transferrin (Fig. 6A) and the HAdV co-localized with the
fluorospheres in these cells (Fig. 6B). Thus, these results
suggest that in the HSB2 cell line, an independent clathrin-Fig. 6. Cell type-dependent uptake pathway of subgroup C adenovirus. (A) Rhoda
cell) were attached to hematopoietic cells 20 min at 4 jC, and the cells were incu
particles, cells were fixed in 1% PFA and analyzed by flow cytometry. Percentages
fluorospheres (20/cell) or rhodamine-labeled transferrin (150 Ag/ml) and FAM-lab
microscopy in A549 cells (upper panel) and HSB2 cells (lower panel).coated pit endocytosis, probably phagocytosis, is the major
endocytic entry route, which does not lead to efficient gene
reporter expression. Further investigations are now per-
formed to confirm this hypothesis. Most B cell lines, except
Daudi, are not able to internalize high level of transferrin.
Apparently, deficient internalization observed previously
(Fig. 5A) could be the result of deficient clathrin-coated
pit endocytosis.
Altered adenovirus-mediated-endosomal membrane lysis in
HSB2 cells in comparison with B cells
Once internalized by endocytosis, the HAdV is con-
tained within endosomes, and subsequent nuclear transfer
requires their release (Greber and Kasamatsu, 1996; Leo-
pold et al., 1998; Miyazawa et al., 2001). This step is
crucial in HAdV trafficking and is limiting for transgene
expression. Endosomal vesicles are separated in early and
late endosomes with, respectively, intravesicular pH of 6.5
and 5.5/6.0, and in lysosomes where acidification occurs
(pH 5.0). We determined the pH environment for endo-
somal escape as previously described (Miyazawa et al.,
2001; Seki et al., 2002; Wang et al., 2000; Wickham et al.,mine-labeled transferrin (150 Ag/ml) or Nile reds-labeled fluorospheres (20/
bated for 10 min at 37 jC. After rinsing in acid buffer to remove attached
of positive cells are shown. (B) Co-localization studies of Nile reds-labeled
eled HAdV (1011 PP/cell) were performed as described below by confocal
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membranes, and its release at different pH, ranging from
5.0 to 7.5, was quantified after HAdV infection. We first
validated this experimental approach in KB3 cells with
subgroup B and C HAdV (Fig. 7A) confirming previously
described results (Greber et al., 1993; Miyazawa et al.,
2001). These works show that HAdV from subgroup B
induce membrane lysis at low pH (5.0–5.5); likewise,
HAdV from subgroup C lyse the KB3 membranes at pH
of 7.0 This methodology was then applied to different
hematopoietic cells. Our results demonstrate that HAdV
from subgroup C (HAdV5) are able to lyse Raji cell
membranes at a pH of 6.5 and U266 cell membranes at
pH of 7.0 (Fig. 7B). For Raji cells, release was alsoFig. 7. Effect of pH on HAdV-dependent membrane lysis. (A) KB3 cells
were incubated 1 h with medium containing [3H]-choline, chilled to 4 jC,
and incubated with 105 PP/cell (HAdV5hgal, open circles) or 5  105 PP/
cells (HAdV3, closed circles). Cells were then incubated with permeabi-
lization buffer at various pH 1 h at 37 jC. The percentage of [3H]-choline
release was determined by comparing the radioactivity in the medium with
the radioactivity remaining in the cells. Values obtained in the absence of
HAdV were subtracted from values obtained in the presence of HAdV. (B)
For HSB2 (closed circles), U266 (open lozenge), and Raji cells (open
square), 1.4  104 PP/cell were used and all incubations were performed in
suspension.observed at pH 5.0 suggesting that when destabilized
adenoviral particles are translocated to lysosomes, HAdV
would be able to lyse these organelles to prevent acidic
degradation. However, when this assay was applied to HSB2
cells, lysis could be observed neither at pH 6.5 nor at pH
7.0. This result strongly suggests that HAdV5hgal is not
able to provoke early endosome membrane lysis in this
HSB2 cell line, which could allow to altered endosomol-
ysis. We could then hypothesized that HAdV is trans-
located to lysosomes where degradation could occur. This
phenomena could explain the exocytose of HAdV sug-
gested by Fig. 5B. However, in addition to different
endocytic pathways, this could explain why no h-galacto-
sidase expression was detected in HSB2 cells after viral
infection (Fig. 1) despite high HAdV binding and uptake
levels (Figs. 4 and 5).Discussion
The major challenge facing gene therapy is the develop-
ment of vectors and delivery systems that can achieve
efficient in vivo gene transfer. Research into gene therapy
for application to a large numbers of hereditary and acquired
diseases is ongoing. At present, the majority (63%) of gene
therapy clinical trials is aimed at treatment of cancer. Most
employ viral vectors including retroviruses (34%) and
HAdV (27%) (JGT, 2003). Present medical treatment pro-
tocols of many diseases involving hematopoietic cells are
often insufficient, so gene transfer approaches are actively
being studied. Hematologic malignancies in which human
gene transfer has been performed include leukemias, lym-
phomas, and cases with a graft-versus-host disease risk after
allogeneic bone marrow transplantation in leukemia and
multiple myeloma (Schmidt-Wolf and Schmidt-Wolf, 2002).
Whereas local injection to cancers with solid tumors is
possible, hematologic malignancies are often systemic and
administration in vivo of a vector is only possible when
using selective tumor targeting. However, an ex vivo
therapy approach allows for a large numbers of cells isolated
from blood to be treated under controlled gene transfer
conditions.
The efficiency of HAdV in transducing human lympho-
cytic cells is controversial and in most cases is insufficient
(Huang et al., 1997; Wattel et al., 1996). Huang et al. (1997)
showed that 40–50% of normal monocytes were transduced
by HAdV, whereas purified normal resting T and B cells
were resistant to infection, but they did not explain the
reason for this. On the other hand, adenoviral vectors
efficiently transduced cell lines derived from human lym-
phocytic malignancies that included Hodgkin disease, Bur-
kitt lymphoma, and myeloma cell lines (Meeker et al.,
1997). In addition, some authors showed efficient adenovi-
ral transduction of murine B lymphocytes, but this transfer
was not cell specific (Li et al., 2001). Recently, the possible
use of these vectors, in particular, in the treatment of B-CLL
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recombinant HAdV expressing CD154 could be used for
gene therapy of chronic lymphocytic leukemia (Wierda et
al., 2000). They showed that HAdV-CD154-transduced and
bystander leukemia cells became effective antigen-present-
ing cells. These cells are responsible of CLL-specific
autologous cytotoxic T lymphocytes production (Takahashi
et al., 2001; Wierda and Kipps, 2000). However, because
the vector used was not B cell specific, high doses were
required to obtain a significant response leading to cytotox-
icity. Thus, it is necessary to create new vectors to optimize
the adenoviral gene transfer efficiency in the treatment of
such diseases.
Adenoviral infection mechanisms have been extensively
studied in permissive cells, but little is known about the
mechanisms involved by hematopoietic cells. These knowl-
edges are crucial for the development of efficient adenoviral
vectors for gene therapy of human lymphocytic malignan-
cies. Thus, to this aim, the present study examined the
cellular events, from plasma membrane binding to gene
expression, of adenoviral transduction in different hemato-
poietic cell lines.
To understand the conflicting results described in the
literature, we analyzed gene expression after infection of
different hematopoietic cell lines with a recombinant
HAdV5 vector containing a h-galactosidase gene reporter
under the control of the immediate early promoter of CMV
(Renaut et al., 2002). This HAdV is E1-deleted and it has
been shown that such viruses can replicate in human trans-
formed cells. However, because hematopoietic cell lines do
not allow transcomplementation of E1, the difference in
susceptibility of each cell lines is probably not due to their
ability to support replication of the vector used. Moreover,
immediate early promoter is the most common promoter
used because of its activity in many cell types. Therefore,
the differences observed in transgene expression are not
probably due to differences in promoter activity, but we
could not exclude this possibility. However, these resultsTable 1
Sensitivity of different cell types to subgroup C Ad
Cell type Epithelial cells B cell lineage
HEK293 A549 HeLa Reh Daudi
Binding +++ ++ +++ ++ +
hCAR ++ ND ND ++ +
CD18 (h2)   ND  +
CD11a (aL)     
Internalization ++ ++ ++ +/ ++
Intracellular viral DNA ++ ++ +++ + ++
Microsphere uptake + ++ + + +
Ad co-localization 
Transferrin uptake ND +++ ++ + +++
Ad co-localization ++
Early endosomolysis ND ND ND ND ND
h-galactosidase +++ ++ ++ + +
ND: not determined.reflect the infection efficiency and our results demonstrate
that B cell lines are more easily transduced than T cells, and
in particular, U266 plasmocytes (Fig. 1).
Several studies suggest that hematopoietic cell lines were
not permissive to subgroup C HAdV transduction because
they express low levels of the primary HAdV receptor
hCAR (Huang et al., 1995; Leon et al., 1998; Nemerow
and Stewart, 1999; Wickham et al., 1996). However, these
studies are controversial. In fact, some cell lines lacking
hCAR appear to be efficiently transduced by nonmodified
HAdV that use alternative HAdV attachment receptors
(Huang et al., 1996; Li et al., 2001; Neering et al., 1996;
Watanabe et al., 1996).
Thus, we analyzed the extracellular and intracellular
steps involved in adenoviral transduction and demonstrated
that there is a relatively good correlation between binding,
uptake, and hCAR levels. Table 1 summarizes the results
concerning the different factors that are known to influence
HAdV infection. We were not able to detect h-galactosidase
gene expression in T cell lines despite levels of HAdV
uptake comparable to those of permissive cells. This is not
the case for B cell lines where the uptake and h-galactosi-
dase gene expression are relatively correlated. U266, Daudi,
and Reh cells showed, respectively, 59%, 4%, and 1% of the
expression level obtained in HEK293. Uptake studies reveal
that only a proportion of the HAdV particles that attach to B
cell membranes is internalized particularly for C, D, and
Reh cells (Fig. 5A). This could be the result of the pattern of
integrins expression on these cells. Indeed, our results
demonstrate that C and D cells express h2 and aL, but not
aM integrins (Fig. 3). Huang et al. suggested that the h2
integrins expressed on hematopoietic cells allow HAdV
vector attachment but not uptake (Huang et al., 1996). In
contrast to their studies, we were not able to detect aM
expression on any of the hematopoietic cell lines tested.
Nevertheless, they examined integrins on only one mono-
cytic cell line. These controversies are probably the results
of varied patterns of CD11b expression, which are depen-T lymphocytes
Raji C D U266 HSB2 Jurkat K562
+ ++ ++ + ++ + +
+ ++ +  +++  
+ ++ ++  ++ + 
+ ++ +  +++ + 
+ + +/ + +++ +++ +/
  + + +++ ++ ++
+ ++ ++ +++ +++ ND ++
+
 +/ +/ + + +/ ++
+
+ ND ND ND  ND ND
   ++   
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(Mac1 a) is mainly expressed on monocytes, granulocytes,
NK cells, CD8+ CTL, and some CD5+ activated B cells. We
detected low expression of integrins avh3 (CD51/61) on
most hematopoietic cell lines in comparison to epithelial cell
lines, confirming previously results showing low basal level
of avh3/5 on hematopoietic cells (Asada-Mikami et al.,
2001). Apparently, these integrins are not implicated in
HAdV fixation on such cells (Huang et al., 1996). Another
explanation for inefficient HAdV uptake in most B cell lines
could be an altered clathrin-coated pit endocytosis as
suggested by transferrin uptake in these cells (Fig. 6A). It
appears that this endocytosis route is not altered in Daudi
cells and could explain why uptake raises 35%. This is
correlated to h-galactosidase gene expression (Fig. 1) that
demonstrated that Daudi cell line is more sensitive than the
other B cell lines (except U266) to HAdV infection. How-
ever, gene reporter expression is weak in Daudi cells that
reflect the low level of attach HAdV particles (Fig. 4). This
is the consequence of low level of hCAR and integrins on
these cells (Figs. 2 and 3).
U266 plasmocytes internalized about 60% of the attached
particles as did HSB2 cells, while permissive A549 cells
internalized 90%. These results could explain the relatively
high h-galactosidase expression obtained with U266 plas-
mocytes and strongly suggest that for engineering of B cell-
specific-modified-HAdV vectors, the endocytic properties
of the targeted cell and its receptor should be taken into
consideration. Our results could not explain why U266
plasmocytes are so permissive to HAdV vectors but confirm
previously results showing the existence of CAR-dependent
and CAR-independent pathways of adenovirus vector-me-
diated gene transfer in fibroblast (Hidaka et al., 1999).
Moreover, it should be noted that other subgroup C HAdV
receptors have been described in the literature, particularly
heparan sulfate (Dechecchi et al., 2001) and a conserved
region of the a-2 domain of the heavy chain of the major
histocompatibility complex class I molecules (Hong et al.,
1997). Thus, further studies need to be performed to
determine how HAdV enter plasmocytes and result in
transgene expression. In particular, we must now test HAdV
permissivity on other plasmocytes cell lines before gener-
alizing this phenomenon.
We analyzed the ability of hematopoietic cells to
internalize transferrin, which is known to entry cells via
clathrin-coated pit endocytosis (Le Borgne and Hoflack,
1998) to determine the role of this endocytic route in
HAdV infection of hematopoietic cells. There is a relative
correlation between the level of transferrin uptake and h-
galactosidase expression (Table 1). Thus, we suggest that
clathrin-coated pit endocytosis is required for efficient
adenoviral infection in hematopoietic cells. Moreover, a
low level of transferrin internalization could be observed in
T cells (HSB2, Jurkat). Taken together with the high
HAdV particle uptake we have observed in HSB2 cells,
these results could suggest that a clathrin-coated pit-inde-pendent endocytic pathway is implicated in HAdV uptake
in such cells. Further investigations need to be performed
to confirm this hypothesis. This could explain why despite
higher copy numbers of adenovirus, impaired transgene
expression is observed in HSB2 cells. Clathrin-coated pit-
independent endocytic pathway has been previously de-
scribed for IL2 receptor entry in T lymphocytes (Lamaze
et al., 2001) and recently for the influenza virus and Ebola
virus (Bavari et al., 2002; Sieczkarski and Whittaker,
2002). Our results suggest that HAdV uptake in HSB2
cells is probably mediated by phagocytosis as shown by
Nile red-labeled fluorosphere uptake and co-localization
studies (Figs. 6A, B). Additional experiments are now
performed to confirm these results. Recent research has
demonstrated that viruses employ the full endocytic ca-
pacity of the cell; this includes clathrin-mediated endocy-
tosis, phagocytosis, caveolae pathways, and non-clathrin
non-caveolae pathways (Sieczkarski and Whittaker, 2002).
It would be of interest to analyze the implication of
caveolae in HAdV internalization. Indeed, recent reports
demonstrated that activated aLh2 integrins are greatly
enriched in the lipid raft compartment of the T cell
membrane (Leitinger and Hogg, 2002). Moreover, activa-
tion of B cells by agonists such as phorbol esters causes
aLh2 mobility in the cell membrane (Kucik et al., 1996).
We are now analyzing expression and function of clathrin
and caveolae to precise entry route of HAdV in B and T
cells.
Another biological barrier to viral transduction could
be endosomolysis. Indeed, the vector can be retained in
endosomes preventing viral DNA transfer into the nucle-
us. We analyzed the ability of HAdV to disrupt the
endosomal membrane in hematopoietic cells. On the basis
of methodology described by Miyazawa et al. (2001) and
Wang et al. (2000), we developed a modified protocol to
examine endosomolysis in these cells. We demonstrated
that HAdV are able to lyse membranes of B cells at pH
of 6.5/7.0, which corresponds to the pH of early endo-
somes (Fig. 7). However, in contrast to Raji and U266
cells, no early (pH 6.5/7.0) membrane lysis was observed
in HSB2 cells suggesting altered endosomolysis. Confor-
mational changes in the viral capsid proteins, induced by
acidic endosomal environment, probably lead to the
exposure of hydrophobic domains able to interact with
the endosomal membrane. This interaction leads to endo-
somal membrane destabilization and release of the virus
into the cytoplasm (Prchla et al., 1995). In our assay, the
same acidic conditions were tested; thus, the difference
observed in membrane lysis capacity could be the result
of different membrane compositions between Raji or
U266 and HSB2 cells modifying adenoviral endosomol-
ysis capacity. Taken together, these results could explain
the absence of h-galactosidase gene expression in HSB2
cells after adenoviral infection (Fig. 8). Moreover, the
absence of endosomal release could explain a possible
exocytose of HAdV in HSB2 cells as suggested in Fig.
Fig. 8. Macropinocytosis and clathrin-coated pit endocytosis of subgroup C HAdV. This figure summarizes the results obtained and is adapted from the review
of Sieczkarski and Whittaker (2002). Here we described two different HAdVendocytic routes in hematopoietic and HAdV-permissive cells. Macropinocytosis
seems to be the major pathway used by HAdV to penetrate into HSB2 and plasmocytes. Escape from early endosomes could explain the efficiency of HAdV
transduction in U266, whereas translocation to lysosomes could explain viral degradation in HSB2 leading to inefficient gene reporter expression. Clathrin-
coated pit endocytosis is the most commonly described entry pathway for permissive cells. It seems that few HAdVenter some B cells using clathrin-coated pit
leading to a low level of h-galactosidase gene expression. CCV, clathrin-coated pit vesicles; EE, early endosomes; LE, late endosomes; LY, lysosomes; ER,
endoplasmic reticulum; NPC, nuclear pore complex; NLS, nuclear localization signal.
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B cell lines to determine if this altered endosomal
membrane lysis is a barrier that is observed in several
T lymphocytes.
In conclusion, we have demonstrated that binding and
uptake of subgroup C HAdV do not necessarily result in
successful infection (Fig. 8). These results confirm valid-
ity of the generally accepted adenovirus gene transfer
model, which requires a variety of factors to be in place
for successful transgene expression. Indeed, in HSB2
cells, we observed that macropinocytosis seems to be
the major route of HAdV entry. This confirms previous
results obtained with the cytomegalovirus indicating that
internalization pathways may be cell type-dependent
(Bodaghi et al., 1999). We further suggest that endo-
somolysis could be deficient in some cells leading toabolition of transgene expression. Thus, this study con-
firms essential findings described for non-hematopoietic
cells, demonstrating that if certain aspects of the basic
binding/uptake/entry mechanisms are deficient or altered,
transduction can be adversely affected (Fig. 8). More
importantly, these results clearly demonstrated that the
use of subgroup C adenovirus, in a gene therapy ap-
proach of treatment of human hematologic malignancies,
requires genetic modifications. This includes considering
aspects of tropism as well as the intracellular steps to
allow for efficient transgene expression in a given cell
type. We are now looking at these considerations to
construct modified adenovirus to allow efficient hemato-
poietic cells infection. The choice of the targeting receptor
is crucial and we will analyze all intracellular steps to
ensure the conservation of endocytosis properties.
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Cell culture
A549 (human epithelial lung carcinoma), KB3 (human
oral carcinoma), HeLa (human uterus carcinoma), and
HEK293 (human embryonic kidney) cells were cultured
in Dulbecco’s Modified Eagle’s medium supplemented
with 10% fetal bovine serum and nonessential amino acids
(1%). Hematopoietic cell lines (Daudi, Jurkat, HSB2,
K562, and Reh) were cultured in RPMI-1640 medium
supplemented with 10% fetal bovine serum. Plasmocytes
U266 and Raji were maintained in RPMI-1640 supple-
mented with 1 mM sodium pyruvate, 12.5 mM HEPES,
and 15% SVF. C and D cell lines were B lymphocytes
obtained from patients, immortalized with the Epstein-Barr
virus (Genethon), and cultured in RPMI supplemented
with 2.5 mM sodium pyruvate, 25 mM HEPES, and
20% SVF. Cells were maintained in a humidified incuba-
tor with 5% CO2. All cell lines were passaged twice a
week.
Adenovirus
A recombinant HAdV5-E1-deleted vector containing a
h-galactosidase reporter gene was previously constructed in
our laboratory (HAdV5hgal) (Renaut et al., 2002). This
HAdV contains the h-galactosidase reporter gene under the
control of the immediate early promoter CMV and was
inserted instead of the E1 region. Wild-type human HAdV
serotypes 2 and 3 were previously purified (D’Halluin et al.,
1978). HAdV amplification was performed in HEK293
cells. Cells were harvested 48 h after infection and four
rounds of freezing and thawing were performed. The cell
extract was then loaded on two successive CsCl gradients as
previously described (D’Halluin et al., 1978). Infectious
particles present in CsCl-purified virus samples were titered
on HEK293 cells (Nyberg-Hoffman et al., 1997), and the
infectious titer was expressed as plaque-forming units per
milliliter (PFU/ml). Physical particles (PP) present in puri-
fied virus sample were estimated from DNA content,
determined by measurement of absorbance at 260 nm. An
absorbance of one corresponds to 1.1  1012 particles per
milliliter (Mittereder et al., 1996).
Adenovirus labeling
For adenoviral protein radiolabeling, HEK293 cells were
infected with 2 pfu/cell of HAdV. Eighteen hours later, cells
were incubated with medium depleted of methionine and
cysteine (INVITROGEN) and supplemented with 2% fetal
bovine serum for 1 h at 37 jC. Promix (1 mCi/108 cells)
[35S]-cell labeling mix (Amersham) was added to cells that
were incubated for 4 h at 37 jC in medium depleted of
methionine and cysteine. Supplementation with 2% of fetal
bovine serum was then performed until a cytopathic effectwas obtain. HAdV vector purification was then performed
as described below.
The conjugation of adenoviral proteins with the car-
boxyfluorescein succimide ester (Molecular Probes) was
performed in 0.1 M carbonate sodium, pH 8.3, as recom-
mended by the manufacturer. 5(6)-Carboxyfluorescein (40
Ag/ml) was added to HAdV and further incubation period of
30 min was observed. The reaction mixture was then trans-
ferred to a dialysis chamber (10000 MW cutoff, Slyde-A-
Lyser, Pierce). Two changes in dialysis buffer (10% glycerol,
10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl2)
were performed overnight at 4 jC. SDS-PAGE analysis of
5(6)-carboxyfluorescein-HAdV was performed: 50 Ag of
protein of nonlabeled and labeled HAdV were separated on
a 4–12% gradient SDS-PAGE and visualized by Coomassie
blue staining and fluorography (STORM 860).
Kinetics of adenovirus binding and uptake
Cells (1.5  106) were plated on six well plates. After
prechilled, cells were incubated 60 min at 4 jC with 106 cpm
of [35S]-radiolabeled HAdV/106 cells. For uptake assays,
incubations for the desired time at 37 jC were then per-
formed. The cells were collected and rinsed once in PBS
before lysis with NaOH, 0.1 N. Radioactivity was measured
in a liquid scintillation analyzer (1600 TR Packard) and the
protein concentration was determined using the Bradford
method (Bradford, 1976) to allow for normalization.
For quantification of uptake using flow cytometric anal-
yses, 1.5  106 cells were incubated with 1011 physical
particles (PP)/ml in 100 Al of 5(6)-FAM-SE HAdV for 60
min at 4 jC. After washing, a chase period of 30 min was
performed at 37 jC. Cells were then treated in the presence
or absence of trypsin 0.25% to remove cell-bound particles.
Quantification of labeled particles was performed, after cell
fixation with 1% paraformaldehyde PFA, by flow cytometry
using an EPICS XL MLC Coulter flow cytometer.
Confocal laser scanning microscopy
For kinetic studies, 5  104 cells were incubated with
1011 PP/ml in 100 Al of 5(6)-FAM-SE HAdV for 1 h at 4
jC. The cells were then centrifuged, resuspended in culture
medium, and incubated for the desired period at 37 jC.
Using the cytospin technique, cells were plated on
microscope slides. Briefly, cells were centrifuged onto a
frosted microscope slide, 5 min at 55  g. Fixation was
performed with paraformaldehyde (PFA) 2%, 20 min at
room temperature (RT). Cells were then treated with 1 mg/
ml RNase I for 20 min at RT. Nuclei were labeled by
incubation with propidium iodide (5 Ag/ml) 5 min at RT.
The preparation was then mounted in Vectashied (Abcys).
Confocal microscopy was performed using a TCS SP
Leica (Lasertechnichk GmbH) microscope, equipped with a
63  objective. An argon–krypton ion laser adjusted at 488
nm was used for fluorescein, 568 nm for propidium iodide
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fluorescence images were obtained. The signal was treated
by line averaging to integrate the signal collected over two
or four lines to reduce noise. The confocal pinhole was
adjusted to allow for a minimum field depth. A focal series
was collected for each specimen. The focal step between
each section was generally 1 Am.
Detection of hCAR, CD18, CD51/61, CD11a, CD11b
For human coxsackie and HAdV receptor (hCAR) de-
tection, cells were incubated 1 h at room temperature with
20 Ag/ml of an affinity purified goat polyclonal antibody
against a peptide mapping near the amino terminus of hCAR
(Santa-Cruz). The cells were then centrifuged, and incuba-
tions with 40 Ag/ml of an anti-goat IgG-FITC were per-
formed for 45 min RT. All incubations were performed in
the presence of 1% bovine serum albumin (BSA). After
fixation in 1% PFA 10 min at RT, cells were then resus-
pended in 1 ml of PBS/BSA (1%). Negative control con-
sisted of cells incubated with an isotype IgG goat (Santa-
Cruz) under the same conditions.
For CD18, CD51/61, CD11a, and CD11b detection, cells
were incubated 1 h at 4 jC with 25 Ag/ml of either anti-
CD18/CD11a/CD11b/CD51-61-FITC (Immunotech) or iso-
types IgG (Immunotech) as negative control. After fixation
in 1% PFA, cells were resuspended in 1 ml of PBS/BSA 1%.
Fluorescent flow cytometric analyses were then performed.
Transferrin and micro-sphere uptake
Cells (106) were incubated with TRITC-labeled transfer-
rin (150 Ag/ml) or with 1 AM Nile red-labeled micro-spheres
(20/cells) 20 min at 4 jC then 10 min at 37 jC. The cells
were rinsed once with acid buffer (0.1 M NaCl, 0.1 M
glycine, pH 3.0) to remove cell surface-bound transferrin or
micro-spheres. After one rinse with PBS/BSA 1%, cells
were fixed with 1% PFA and resuspended in PBS/BSA 1%
for cytometric analyses.
Co-localization studies were performed as described
below, except that incubations were performed in the
presence of 1011 PP/ml of FAM-labeled HAdV2. Cells were
cytospin and analyzed using confocal microscopy as de-
scribed in Confocal laser scanning microscopy section.
Membrane permeabilization assay
HAdV-induced cell membrane lysis was assayed, as
previously described (Miyazawa et al., 2001; Wang et al.,
2000), by measuring [3H]-choline release. For this, KB3 cells
were seeded on 96-well plates at a density of 2 104 cells per
well. Twenty-four hours later, cells were washed twice with
DMEM containing 0.2% BSA and then incubated with [3H]-
choline (5 ACi/ml) for 1 h at 37 jC in culture medium. Cells
were prechilled on ice and washed three times with ice-cold
virus binding buffer (10 mM HEPES, pH 7.0, 0.9% NaCl,0.2% BSA, 1 mM CaCl2, 1 mM MgCl2, 50 mM NaN3).
Infection was then performed 1 h at 4 jC in the presence of
105 or indicated viral PP per cell. Cells were then rinsed once
with permeabilization buffer prepared by titrating morpholi-
neethanesulfonic acid (MES)-buffered saline (100 mMMES,
pH 5.0, 0.9% NaCl, 0.2% BSA, 1 mM CaCl2, 1 mM MgCl2,
and 50 mM NaN3) with HEPES-buffered saline to achieve
the desired pH range from 5.0 to 7.5. Cells were then
incubated 1 h at 37 jC in the presence of permeabilization
buffer. This buffer was collected to determine [3H]-choline
release and cells were lysed with 0.1 NNaOH for 1 h at 37 jC
to measure cell-associated [3H]-choline.
Radioactivity was measured in a liquid scintillation ana-
lyzer (1600 TR Packard). The percentage of [3H]-choline
release was calculated from the equation: radioactivity in
medium  100/(radioactivity in cells + radioactivity in
medium). Percentage of radioactivity obtained in the absence
of adenovirus was sustained for percentage obtained in the
presence of adenovirus to set free from nonspecific lysis.
For hematopoietic cells, 106 cells were suspended in
RPMI containing 0.2% BSA and were treated as described
below, except that all incubations were performed in
suspension.
b-Galactosidase assay
Adherent cells and cells in suspension were seeded on 6-
wells cell culture plates at a density of 1.5  106 cells per
well and incubated at 37 jC. Cells were then infected at a
multiplicity of infection (MOI) of 30 pfu (corresponding to
1000 physical particles per cell) of HAdV5hgal vector 2 h at
37 jC in serum-free medium. Medium with 4% SVF was
added for a further postinfection period of 24 h at 37 jC,
and h-galactosidase reporter gene detection was then per-
formed using a h-gal enzyme assay (Promega). For deter-
mination of the percentage of positive cells, HAdV5hgal
infection was performed as described above. After 24-
h postinfection period, the cells were collected and h-
galactosidase reporter gene detection was then performed
using standard assay with o-nitrophenyl-h-D-galactopyrano-
side as substrate.
Real-time PCR
Klein et al. (1999) have described the principle of real-
time PCR for quantification of viral DNA. Genomic and
viral DNAwere extracted simultaneously from cells using a
QIAamp DNA mini kit (Qiagen). To amplify the adenoviral
DNA, the following primers were used: HAdV5 forward
primer 5V-TTCTGCGCTAAGATTGTCAGTTTC-3V (6121–
6144) and HAdV5 reverse primer 5V-GCCCGACGAGCG-
CAC-3V (6409–6395). To detect amplification, a probe 5-
CGCGATGTTTAGCTGCACGTATTCGC-3 (6377–6362)
carrying a fluorescent group (6-carboxyfluorescein, FAM)
in 5Vand a quencher dye (6-carboxytetramethylrhodamine,
TAMRA) in 3Vwas used.
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gene was performed for the same sample, using primers and
probes previously described (Gault et al., 2001). All primers
were used at 300 nM, probes were used at 400 nM for HAdV
DNA detection and 200 nM for albumin DNA detection.
DNA amplification was performed in a 25-Al mixture with
PCR Supermix UDG (INVITROGEN). The reaction mixture
contained 5 Al of DNA, 1.5 units of Platinium Taq DNA
polymerase, 20 mM Tris–HCl (pH 8.4), 50 mM KCl, 3 mM
MgCl2, 0.2 mM dGTP, 0.2 mM dATP, 0.2 mM dCTP, 0.4
mM dUTP, and 1 unit of UDG.
The positive control consists of a plasmid (pRECad)
containing the targeted sequences (Renaut et al., 2002). A
standard graph of the Ct values obtained from serial dilutions
(104 to 1 ng) was performed for both HAdV vectors and the
albumin gene. The results are presented as the ratio of ng
HAdV DNA/ng albumin DNA. The PCR was initiated with
activation of UDG 2 min at 50 jC and dsDNA denaturation
for 10 min at 95 jC. Amplification occurred during 50
cycles consisting of 15 s at 95 jC and 1 min at 60 jC.Acknowledgments
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